Unknown

Dataset Information

0

Highly efficient therapeutic gene editing of human hematopoietic stem cells.


ABSTRACT: Re-expression of the paralogous ?-globin genes (HBG1/2) could be a universal strategy to ameliorate the severe ?-globin disorders sickle cell disease (SCD) and ?-thalassemia by induction of fetal hemoglobin (HbF, ?2?2)1. Previously, we and others have shown that core sequences at the BCL11A erythroid enhancer are required for repression of HbF in adult-stage erythroid cells but are dispensable in non-erythroid cells2-6. CRISPR-Cas9-mediated gene modification has demonstrated variable efficiency, specificity, and persistence in hematopoietic stem cells (HSCs). Here, we demonstrate that Cas9:sgRNA ribonucleoprotein (RNP)-mediated cleavage within a GATA1 binding site at the +58 BCL11A erythroid enhancer results in highly penetrant disruption of this motif, reduction of BCL11A expression, and induction of fetal ?-globin. We optimize conditions for selection-free on-target editing in patient-derived HSCs as a nearly complete reaction lacking detectable genotoxicity or deleterious impact on stem cell function. HSCs preferentially undergo non-homologous compared with microhomology-mediated end joining repair. Erythroid progeny of edited engrafting SCD HSCs express therapeutic levels of HbF and resist sickling, while those from patients with ?-thalassemia show restored globin chain balance. Non-homologous end joining repair-based BCL11A enhancer editing approaching complete allelic disruption in HSCs is a practicable therapeutic strategy to produce durable HbF induction.

SUBMITTER: Wu Y 

PROVIDER: S-EPMC6512986 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


Re-expression of the paralogous γ-globin genes (HBG1/2) could be a universal strategy to ameliorate the severe β-globin disorders sickle cell disease (SCD) and β-thalassemia by induction of fetal hemoglobin (HbF, α<sub>2</sub>γ<sub>2</sub>)<sup>1</sup>. Previously, we and others have shown that core sequences at the BCL11A erythroid enhancer are required for repression of HbF in adult-stage erythroid cells but are dispensable in non-erythroid cells<sup>2-6</sup>. CRISPR-Cas9-mediated gene modifi  ...[more]

Similar Datasets

| S-EPMC8120141 | biostudies-literature
| S-EPMC7869435 | biostudies-literature
| S-EPMC9839747 | biostudies-literature
| S-EPMC5598083 | biostudies-literature
| S-EPMC7610558 | biostudies-literature
| S-EPMC9171380 | biostudies-literature
| S-EPMC5087995 | biostudies-literature
| S-EPMC6348980 | biostudies-literature
| S-EPMC6735704 | biostudies-literature